Fluorouracil Tablets

It is first converted into 5-fluoro-2-deoxyuridine nucleotide in the body, which inhibits thymine nucleotide synthetase, blocking the conversion of deoxyuridine nucleotide into deoxythymine nucleotide, thereby inhibiting DNA biosynthesis. In addition, it can also be incorporated into RNA, inhibiting RNA synthesis by preventing uracil and orotic acid from incorporating into RNA. This product is a cell cycle-specific drug that mainly inhibits S-phase tumor cells.

The main ingredient of this product is: fluorouracil.

This product is white tablets.

It is the main chemotherapy drug for malignant hydatidiform mole and choriocarcinoma. It is also used for adjuvant chemotherapy and palliative treatment of breast cancer, digestive tract tumors (including primary and metastatic liver cancer and pancreatic cancer), ovarian cancer and primary bronchial lung cancer.

The usual dosage for adults is 0.15-0.3g per day, divided into 3-4 doses. The total dosage for a course of treatment is 10-15g.

1. Nausea, loss of appetite or vomiting, usually not serious with most doses, oral mucosal inflammation or ulcers, abdominal discomfort or diarrhea occasionally. Peripheral blood leukopenia is common (mostly reaches the lowest point within 2 to 3 weeks after the start of the course of treatment, and returns to normal after about 3 to 4 weeks), and thrombocytopenia is rare. Cough, shortness of breath or cerebellar ataxia are extremely rare; 2. Long-term use can lead to nervous system toxicity; 3. Occasionally, myocardial ischemia after medication may occur, and angina pectoris and electrocardiogram changes may occur. If confirmed cardiovascular reactions (arrhythmia, angina pectoris, ST segment changes) occur, fluorouracil can no longer be used because of the risk of sudden death.

A very small number of human cases have been diagnosed with congenital malformations due to the use of this drug within the first three months of pregnancy, and this may have long-term effects on the fetus. Therefore, this drug is contraindicated in women within the first three months of pregnancy. Due to the potential mutagenicity, teratogenicity and carcinogenicity of this drug and the possible toxic and side effects in infants, breastfeeding is not allowed during the use of this drug. This drug is contraindicated when accompanied by varicella or herpes zoster. Fluorouracil is contraindicated for use in debilitated patients.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Women are prohibited from using this drug within the first three months of pregnancy. Breastfeeding is prohibited during the use of this product. Precautions for the elderly: Not yet clear.

It has been reported that a variety of drugs can biochemically affect the anti-cancer effect or toxicity of fluorouracil, common drugs include methotrexate, metronidazole and tetrahydrofolate. When used in combination with methotrexate, methotrexate should be given 4 to 6 hours before fluorouracil, otherwise the effect will be reduced. Giving tetrahydrofolate first and then fluorouracil can increase its efficacy. This product can generate a neurotoxic metabolite - fluorocitric acid, which can cause cerebral palsy, so it cannot be injected intrathecally. When using this product, it is not advisable to drink alcohol or use aspirin drugs at the same time to reduce the possibility of gastrointestinal bleeding. Allopurinol can reduce the bone marrow suppression caused by fluorouracil.

Keep away from light and store in a sealed container.

50mg

24 months

Shanxi Xinyu Pharmaceutical Co., Ltd.

• Founded in:

  2003-07-16

• Address:

  No. 1 Road, Huitong Industrial Park, Jinzhong Development Zone, Shanxi Demonstration Zone, Jinzhong City, Shanxi Province

• Tax NO.:

  91140700729643238M

• Registered Funds:

  18.717245 million yuan

• Website:

  Log in to view

• Email:

  Log in to view